The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| HRGN | -38.91% | -16% | -3.43% | -99% |
| S&P | +12.16% | +74.91% | +11.82% | +290% |
Biostage, Inc. is a biotechnology company, which engages in the development of organ implants to treat congenital defects, cancers, and life-threatening conditions of the esophagus, bronchus and trachea. It operates through Cellframe technology, engineered to stimulate the body's signaling pathways and natural healing process to regenerate and restore organ function. The company was founded on May 3, 2012 and is headquartered in Holliston, MA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $123.00K | 108.5% |
| Gross Profit | -$14.00K | 83.5% |
| Gross Margin | -11.38% | 132.7% |
| Market Cap | $33.99M | -62.4% |
| Market Cap / Employee | $4.25M | 0.0% |
| Employees | 8 | 0.0% |
| Net Income | -$1,700.00K | 8.6% |
| EBITDA | -$1,689.00K | 5.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $1.32M | -63.3% |
| Accounts Receivable | $3.00K | 200.0% |
| Inventory | 0 | -80.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $116.00K | -48.2% |
| Short Term Debt | $108.00K | 2.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -166.12% | 14.5% |
| Return On Invested Capital | -291.01% | 96.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1,402.00K | 4.9% |
| Operating Free Cash Flow | -$1,402.00K | 4.9% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 12.35 | 9.54 | 13.21 | 41.42 | -114.78% |
| Price to Sales | 104.40 | 76.93 | 39.86 | 45.39 | -87.49% |
| Price to Tangible Book Value | 12.35 | 9.54 | 13.21 | 41.42 | -114.77% |
| Enterprise Value to EBITDA | -32.10 | -18.76 | -14.71 | -19.32 | -57.96% |
| Return on Equity | -317.7% | -662.3% | -2839.1% | -242.0% | -3.43% |
| Total Debt | $547.00K | $430.00K | $312.00K | $224.00K | -31.91% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
